{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T10:19:53Z","timestamp":1780654793262,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s00277-021-04429-8","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T06:03:16Z","timestamp":1612245796000},"page":"691-698","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-219X","authenticated-orcid":false,"given":"Liudmila V.","family":"Fedorova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill V.","family":"Lepik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia B.","family":"Mikhailova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Kondakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri R.","family":"Zalyalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim V.","family":"Baykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Babenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey V.","family":"Kozlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan S.","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris V.","family":"Afanasyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"issue":"14","key":"4429_CR1","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, de Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM (2018) Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36(14):1428\u20131439. https:\/\/doi.org\/10.1200\/JCO.2017.76.0793","journal-title":"J Clin Oncol"},{"issue":"19","key":"4429_CR2","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH, for the KEYNOTE-087 (2017) KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 35(19):2125\u20132132. https:\/\/doi.org\/10.1200\/JCO.2016.72.1316","journal-title":"J Clin Oncol"},{"issue":"3","key":"4429_CR3","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1158\/1078-0432.ccr-18-0793","volume":"25","author":"M Gauci","year":"2019","unstructured":"Gauci M, Lanoy E, Champiat S, Caramella C et al (2019) Long-term survival in patients responding to anti-PD-1\/PD-L1 therapy and disease outcome upon treatment discontinuation. Clinical Cancer Research 25(3):946\u2013956. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-0793","journal-title":"Clinical Cancer Research"},{"key":"4429_CR4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1186\/s12885-018-4819-2","volume":"18","author":"M Tachihara","year":"2018","unstructured":"Tachihara M, Negoro S, Inoue T, Tamiya M, Akazawa Y, Uenami T, Urata Y, Hattori Y, Hata A, Katakami N, Yokota S (2018) Efficacy of anti-PD-1\/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer 18:946. https:\/\/doi.org\/10.1186\/s12885-018-4819-2","journal-title":"BMC Cancer"},{"issue":"7","key":"4429_CR5","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/annonc\/mdz110","volume":"30","author":"YJL Jansen","year":"2019","unstructured":"Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, M\u00e4kel\u00e4 S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B (2019) Discontinuation of anti-PD-antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Annals of Oncology 30(7):1154\u20131161. https:\/\/doi.org\/10.1093\/annonc\/mdz110","journal-title":"Annals of Oncology"},{"issue":"3","key":"4429_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.2018.36.15_suppl.e15086","volume":"1","author":"ZW Myint","year":"2018","unstructured":"Myint ZW, Arays R, Raajasekar AKA, Wang P (2018) Long-term outcomes in patients after discontinuation of immune checkpoint inhibitors. J Clin Res Med 1(3):1\u20134. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.e15086","journal-title":"J Clin Res Med"},{"key":"4429_CR7","doi-asserted-by":"publisher","unstructured":"Atkinson VG, Ladwa R (2016) Complete responders to anti-PD1 antibodies. What happens when we stop? Ann Oncol 27(6):1116P. https:\/\/doi.org\/10.1093\/annonc\/mdw379.11","DOI":"10.1093\/annonc\/mdw379.11"},{"key":"4429_CR8","doi-asserted-by":"publisher","first-page":"e15086","DOI":"10.1200\/JCO.2018.36.15_suppl.e15086","volume":"36","author":"Z Myint","year":"2018","unstructured":"Myint Z, Arays R, Raajasekar AKA, Huang B, Chen Q, Wang P (2018) Long-term outcomes in patients after discontinuation of PD1\/PDL1 inhibitors. J Clin Oncol 36:e15086. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.e15086","journal-title":"J Clin Oncol"},{"key":"4429_CR9","doi-asserted-by":"crossref","unstructured":"Spigel DR, et al (2017) CHECKMATE153: Randomized results of continuous vs 1-year fixed-duration nivolumab in patients with advanced non-small cell lung cancer. Ann Oncol 28:5. Abstract 1297O. https:\/\/www.primeoncology.org\/app\/uploads\/prime_activities\/42584\/VPS_Madrid_1297O_Lung_Spigel.pdf","DOI":"10.1093\/annonc\/mdx380.002"},{"key":"4429_CR10","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1182\/blood-2018-03-841262","volume":"131","author":"G Manson","year":"2018","unstructured":"Manson G, Herbaux C, Brice P, Bouabdallah K, Stamatoullas A, Schiano JM, Ghesquieres H, Dercle L, Houot R, Lymphoma Study Association (2018) Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma. Blood 131:2856\u20132859. https:\/\/doi.org\/10.1182\/blood-2018-03-841262","journal-title":"Blood"},{"key":"4429_CR11","unstructured":"Lepik K, Fedorova L, Mikhailova N et al (2019) Cessation of immune checkpoint inhibitors therapy in r\/r Hodgkin lymphoma: should we consider HSCT? 45th Annual Meeting of the European Society for Blood and Marrow Transplantation, Abstract collection. Poster number A232"},{"key":"4429_CR12","unstructured":"Goodman A (2017) Retreatment with checkpoint inhibitors may be feasible for some patients with NSCLC. The ASCO post. https:\/\/www.ascopost.com\/issues\/july-10-2017\/retreatment-with-checkpoint-inhibitors-may-be-feasible-for-some-patients-with-nsclc. Accessed 10 June 2017"},{"issue":"15","key":"4429_CR13","doi-asserted-by":"publisher","first-page":"9012","DOI":"10.1200\/JCO.2017.35.15_suppl.9012","volume":"35","author":"FC Santini","year":"2017","unstructured":"Santini FC, Rizvi H, Wilkins O, van Voorthuysen M, Panora E, Halpenny D, Kris MG, Rudin CM, Chaft JE, Hellmann MD (2017) Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol 35(15):9012. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.9012","journal-title":"J Clin Oncol"},{"key":"4429_CR14","doi-asserted-by":"crossref","unstructured":"Fujita K, Uchida N, Yamamoto Y, et al (2019) Retreatment with anti-PD-L1 antibody in advanced non-small cell lung cancer previously treated with anti-PD-1 antibodies. Anticancer Research 39(7):3917\u20133921. 10.21873\/anticanres.13543","DOI":"10.21873\/anticanres.13543"},{"issue":"7","key":"4429_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1200\/JCO.2019.37.7_suppl.652","volume":"37","author":"SA Alaiwi","year":"2019","unstructured":"Alaiwi SA, Martini DJ, Xie W et al (2019) Safety and efficacy of restarting immune checkpoint inhibitors (ICI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 37(7):652\u2013652. https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.652","journal-title":"J Clin Oncol"},{"key":"4429_CR16","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","volume":"29","author":"MH Pollack","year":"2018","unstructured":"Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN (2018) Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 29:250\u2013255. https:\/\/doi.org\/10.1093\/annonc\/mdx642","journal-title":"Ann Oncol"},{"key":"4429_CR17","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/annonc\/mdu441","volume":"25","author":"C Lebb\u00e9","year":"2014","unstructured":"Lebb\u00e9 C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day SJ, Konto C, Cykowski L, McHenry MB, Wolchok JD (2014) Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 25:2277\u20132284. https:\/\/doi.org\/10.1093\/annonc\/mdu441","journal-title":"Ann Oncol"},{"key":"4429_CR18","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/bjc.2014.126","volume":"110","author":"V Chiarion-Sileni","year":"2014","unstructured":"Chiarion-Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabr\u00f2 L, Marchetti P, de Galitiis F, Testori A, Ferrucci PF, Queirolo P, Spagnolo F, Quaglino P, Carnevale Schianca F, Mandal\u00e0 M, di Guardo L, del Vecchio M (2014) Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer 110:1721\u20131726. https:\/\/doi.org\/10.1038\/bjc.2014.126","journal-title":"Br J Cancer"},{"key":"4429_CR19","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-12-3080","volume":"19","author":"C Robert","year":"2013","unstructured":"Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S, MDX010-20 investigators (2013) Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 19:2232\u20132239. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3080","journal-title":"Clin Cancer Res"},{"key":"4429_CR20","unstructured":"Maiko N, Nakaya A, Kurata T, et al (2018) Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. Oncotarget 9(64):32298\u201332304. 10.18632\/oncotarget.25949"},{"issue":"6","key":"4429_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4172\/1948-5956.1000534","volume":"10","author":"C Pellegrini","year":"2018","unstructured":"Pellegrini C, Casadei B, Cellini C, Argnani L, Cavo M, Zinzani PL (2018) Sequential double bridging to transplant with diversified anti-PD1 monoclonal antibodies retreatment in relapsed Hodgkin lymphoma: a case report. J Cancer Sci Ther 10(6):149. https:\/\/doi.org\/10.4172\/1948-5956.1000534","journal-title":"J Cancer Sci Ther"},{"key":"4429_CR22","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1182\/blood.2019000324","volume":"134","author":"R Chen","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH (2019) Pembrolizumab in relapsed or refractory Hodgkin lymphoma: two-year follow-up of KEYNOTE-087. Blood. 134:1144\u20131153. https:\/\/doi.org\/10.1182\/blood.2019000324","journal-title":"Blood."},{"key":"4429_CR23","doi-asserted-by":"publisher","unstructured":"Lepik KV, Mikhailova NB, Moiseev IS, et al (2019) Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT\u00adna\u00efve patients. Leukemia & Lymphoma 1\u20134. https:\/\/doi.org\/10.1080\/10428194.2019.1573368","DOI":"10.1080\/10428194.2019.1573368"},{"key":"4429_CR24","doi-asserted-by":"crossref","unstructured":"Kozlov AV, Kazantzev IV, Iukhta TV, et al (2019) Nivolumab in pediatric Hodgkin\u2019s lymphoma. CTT. 10.18620\/ctt-1866-8836-2019-8-4-41-48","DOI":"10.18620\/ctt-1866-8836-2019-8-4-41-48"},{"key":"4429_CR25","doi-asserted-by":"publisher","unstructured":"Lepik KV, Fedorova LV, Kondakova EV et al (2020) A phase 2 study of nivolumab using a fixed dose of 40 mg (Nivo40) in patients with relapsed\/refractory Hodgkin lymphoma. Hemasphere 4(5):480. 2020 https:\/\/doi.org\/10.1097\/HS9.0000000000000480","DOI":"10.1097\/HS9.0000000000000480"},{"key":"4429_CR26","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","volume":"6","author":"Y Shi","year":"2019","unstructured":"Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, Jin C, Zou L, Qiu L, Li W, Yang J, Hou M, Zeng S, Zhang Q, Hu J, Zhou H, Xiong Y, Liu P (2019) Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (Orient-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol 6:e12\u2013e19. https:\/\/doi.org\/10.1016\/S2352-3026(18)30192-3","journal-title":"Lancet Haematol"},{"key":"4429_CR27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1182\/blood-2018-99-117848","volume":"132","author":"Y Song","year":"2018","unstructured":"Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q, Lv F, Yang Y, Guo H, Yang L, Elstrom R, Huang J, Novotny W, Wei V, Zhu J (2018) Tislelizumab (Bgb-A317) for relapsed\/refractory classical Hodgkin lymphoma: preliminary efficacy and safety results from a phase 2 study. Blood 132:682. https:\/\/doi.org\/10.1182\/blood-2018-99-117848","journal-title":"Blood"},{"key":"4429_CR28","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1200\/JCO.18.02151","volume":"37","author":"J Nie","year":"2019","unstructured":"Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, Li X, Liu J, Ku W, Zhang Y, Chen M, An X, Shi L, Brock MV, Bai J, Han W (2019) Addition of low-dose decitabine to anti-Pd-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma. J Clin Oncol 37:1479\u20131489. https:\/\/doi.org\/10.1200\/JCO.18.02151","journal-title":"J Clin Oncol"},{"key":"4429_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/hon.2437_54","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Gibb AL, Collins GP, Popat R, el-Sharkawi D, Burton C, Lewis D, Miall FM, Forgie A, Compagnoni A, Andreola G, Brar S, Thall A, Woolfson A, Radford J (2017) Blockade of the PD-1 checkpoint with anti\u2013PD-L1 antibody Avelumab is sufficient for clinical activity in relapsed\/refractory classical Hodgkin lymphoma (cHL). Hematol Oncol 35:67. https:\/\/doi.org\/10.1002\/hon.2437_54","journal-title":"Hematol Oncol"},{"key":"4429_CR30","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1182\/blood-2018-99-118198","volume":"132","author":"M Hamadani","year":"2018","unstructured":"Hamadani M, Collins GP, Samaniego F, Spira AI, Davies A, Radford J, Caimi P, Menne T, Boni J, Cruz H, Feingold J, He S, Wuerthner J, Horwitz SM (2018) Phase 1 study of Adct-301 (Camidanlumab Tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed\/refractory classical Hodgkin lymphoma. Blood 132:928. https:\/\/doi.org\/10.1182\/blood-2018-99-118198","journal-title":"Blood"},{"key":"4429_CR31","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","volume":"125","author":"A Rothe","year":"2015","unstructured":"Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, Ravic M, Knackmuss S, Marschner JP, Pogge von Strandmann E, Borchmann P, Engert A (2015) A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct Afm13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 125:4024\u20134031. https:\/\/doi.org\/10.1182\/blood-2014-12-614636","journal-title":"Blood"},{"key":"4429_CR32","unstructured":"Smith SM, Sch\u00f6der H, Johnson JL, et al (2013) The Anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: cancer and leukemia group B 50602 (Alliance) Leukemia & Lymphoma 54:1405\u20131410. 10.3109\/10428194.2012.744453"},{"key":"4429_CR33","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1182\/blood.V116.21.284.284","volume":"116","author":"AS Freedman","year":"2010","unstructured":"Freedman AS, Kuruvilla J, Assouline SE et al (2010) Clinical activity of lucatumumab (Hcd122) in patients (Pts) with relapsed\/refractory Hodgkin or non-Hodgkin lymphoma treated in a phase Ia\/II clinical trial (NCT00670592). Blood 116:284. https:\/\/doi.org\/10.1182\/blood.V116.21.284.284","journal-title":"Blood"},{"key":"4429_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000401","volume":"4","author":"KV Lepik","year":"2020","unstructured":"Lepik KV, Mikhailova NB, Kondakova EV, Zalyalov YR, Fedorova LV, Tsvetkova LA, Kotselyabina PV, Borzenkova ES, Babenko EV, Popova MO, Darskaya EI, Baykov VV, Moiseev IS, Afanasyev BV (2020) A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed\/refractory Hodgkin lymphoma after nivolumab monotherapy failure. HemaSphere 4:e401. https:\/\/doi.org\/10.1097\/HS9.0000000000000401","journal-title":"HemaSphere"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-021-04429-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T10:24:10Z","timestamp":1614421450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-021-04429-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["4429"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04429-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"1 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was performed in accordance with the 1964 Helsinki declaration and approved by the institutional review board. All enrolled patients gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Materials availability"}}]}}